6533b826fe1ef96bd1285297
RESEARCH PRODUCT
Could the Combined Administration of Bone Antiresorptive Drug, Taxanes, and Corticosteroids Worsen Medication Related Osteonecrosis of the Jaws in Cancer Patients?
Vera PanzarellaGiacomo OteriIlaria MorrealeAntonia MarcianòAntonio PiconeRiccardo NuceraOlga Di FedeGiuseppina Campisisubject
DrugGenetics and Molecular Biology (all)Malemedicine.medical_specialtyExacerbationArticle SubjectImmunology and Microbiology (all)media_common.quotation_subjectlcsh:MedicineClinical manifestationBiochemistryGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineAdrenal Cortex HormonesInternal medicineNeoplasmsmedicineHumansDrug InteractionsStage (cooking)media_commonRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)General Immunology and MicrobiologyBone Density Conservation AgentsDiphosphonatesbusiness.industrylcsh:ROsteonecrosisSoft tissueCancer030206 dentistryGeneral Medicinemedicine.diseaseZoledronic acidBiochemistry Genetics and Molecular Biology (all) Immunology and Microbiology (all)Italy030220 oncology & carcinogenesisBisphosphonate-Associated Osteonecrosis of the JawFemaleTaxoidsbusinessOsteonecrosis of the jawBiochemistry Genetics and Molecular Biology (all); Immunology and Microbiology (all)medicine.drugResearch Articledescription
The study presents a report of 58 metastatic cancer patients who developed osteonecrosis of the jaws after being treated with zoledronic acid and taxanes, plus corticosteroids. A retrospective analysis of data registered in the archives of two Italian osteonecrosis of the jaws treatment centers, who are based at the University of Messina and at the University of Palermo, was performed in order to study, in these patients, demographic data and characteristics such as frequency of cancer location, lines of therapy, frequency of cancer drugs, presence/absence of oral trigger, number, location, and stage of jaw osteonecrosis. It was found that the majority of patients developed advanced stages of osteonecrosis, frequently complicated with infection. It was hypothesized that the concurrent administration of chemotherapeutic agents could be eventually considered as a factor able to allow a faster worsening of the clinical manifestation through the exacerbation of soft tissue defects, due to chemotherapy drugs.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2018-05-01 | BioMed Research International |